期刊
HEPATOLOGY
卷 76, 期 4, 页码 1203-1218出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1002/hep.32613
关键词
-
资金
- Instituto de Salud Carlos III [PI044031, PI18]
- National Comprehensive Cancer Network
Hepatocellular carcinoma is a global health challenge, and liver transplantation is the best long-term treatment option. Locoregional methods for downstaging have limitations, while systemic treatments show potential for downstaging before transplantation. Assessment, endpoints, and clinical trial designs are critical considerations.
Hepatocellular carcinoma remains a global health challenge affecting close to 1 million cases yearly. Liver transplantation provides the best long-term outcomes for those meeting strict criteria. Efforts have been made to expand these criteria, whereas others have attempted downstaging approaches. Although locoregional approaches to downstaging are appealing and have demonstrated efficacy, limitations and challenges exists including poor imaging modality to assess response and appropriate endpoints along the process. Recent advances in systemic treatments including immune checkpoint inhibitors alone or in combination with tyrosine kinase inhibitors have prompted the discussion regarding their role for downstaging disease prior to transplantation. Here, we provide a review of prior locoregional approaches for downstaging, new systemic agents and their role for downstaging, and finally, key and critical considerations of the assessment, endpoints, and optimal designs in clinical trials to address this key question.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据